Simple Summary Circulating tumor DNA is DNA released by the tumor into the bloodstream.
In breast cancer, it is used mainly in research or in clinical trials, but it will likely be used in …

Liquid biopsy is a technique that utilizes circulating biomarkers in the body fluids of cancer
patients to provide information regarding the genetic landscape of the cancer. It is emerging …

Malignant tumors shed DNA into the circulation. The transient half-life of circulating tumor
DNA (ctDNA) may afford the opportunity to diagnose, monitor recurrence, and evaluate …

Citrullinated histone H3 (H3Cit) is a central player in the neutrophil release of nuclear
chromatin, known as neutrophil extracellular traps (NETs). NETs have been shown to elicit …

Circulating cell-free DNA (cfDNA) has been suggested as a cancer biomarker. Several
studies assessed the usefulness of quantitative and qualitative tumor-specific alterations of …

The existence of extracellular DNA in human plasma, also known as cell‐free DNA (cf DNA),
was first described in the 1940s. In recent years, there has been a resurgence of interest in …

Breast cancer management has progressed immensely over the decades, but the disease is
still a major source of morbidity and mortality worldwide. Even with enhanced imaging …

Detection of plasma circulating nucleic acids (CNAs) requires the use of extremely sensitive
and precise methods. The commonly used quantitative real-time polymerase chain reaction …

There is a strong demand for the identification of new biomarkers in colorectal cancer (CRC)
diagnosis. Among all liquid biopsy analysts, cell-free circulating DNA (cfDNA) is probably …

While identifying genomic alterations in tumor tissue is the current gold-standard technique
for molecular profiling, circulating tumor DNA (ctDNA) represents a noninvasive method of …